494 results match your criteria: "Crump Institute for Molecular Imaging[Affiliation]"
Microfluid Nanofluidics
October 2010
Department of Molecular & Medical Pharmacology, Crump Institute for Molecular Imaging, California NanoSystems Institute, David Geffen School of Medicine, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095 USA.
Using liquid slugs as microreactors and microvessels enable precise control over the conditions of their contents on short-time scales for a wide variety of applications. Particularly for screening applications, there is a need for control of slug parameters such as size and composition. We describe a new microfluidic approach for creating slugs in air, each comprising a size and composition that can be selected individually for each slug.
View Article and Find Full Text PDFCancer Res
November 2010
Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, USA.
Oncogenic kinase activity and the resulting aberrant growth and survival signaling are a common driving force of cancer. Accordingly, many successful molecularly targeted anticancer therapeutics are directed at inhibiting kinase activity. To assess kinase activity in minute patient samples, we have developed an immunocapture-based in vitro kinase assay on an integrated polydimethylsiloxane microfluidics platform that can reproducibly measure kinase activity from as few as 3,000 cells.
View Article and Find Full Text PDFMol Imaging Biol
October 2011
Department of Medical and Molecular Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
Purpose: PETbox is a low cost bench top preclinical PET scanner dedicated to pharmacokinetic and pharmacodynamic mouse studies. A prototype system was developed at our institute, and this manuscript characterizes the performance of the prototype system.
Procedures: The PETbox detector consists of a 20 × 44 bismuth germanate crystal array with a thickness of 5 mm and cross-section size of 2.
Protein Eng Des Sel
October 2010
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, California Nanosystems Institute, University of California, Los Angeles, 570 Westwood Plaza, CA 90095-1770, USA.
The long circulation persistence of human serum albumin (HSA) is enabled by its domain III (DIII) interaction with the neonatal Fc receptor (FcRn). A protein scaffold based on HSA DIII was designed. To modify the serum half life of the scaffold, residues H535, H510, and H464 were individually mutated to alanine.
View Article and Find Full Text PDFBiosystems
March 2011
Crump Institute for Molecular Imaging, UCLA, 570 Westwood Plaza, Building 114, Los Angeles, CA 90095, USA.
It is evident that complex animate materials, which operate far from equilibrium, exhibit sensory responses to the environment through emergent patterns. Formation of such patterns is often the underlying mechanism of an active response to environmental changes and can be interpreted as a result of the distributed parallel information processing taking place within the material. Such emergent patterns are not limited to biological entities; indeed there is a wide range of complex nonlinear dissipative systems which exhibit interesting emergent patterns within a range of parameters.
View Article and Find Full Text PDFOncogene
November 2010
Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095-7227, USA.
BCR-ABL1 is a fusion tyrosine kinase, which causes multiple types of leukemia. We used an integrated proteomic approach that includes label-free quantitative protein complex and phosphorylation profiling by mass spectrometry to systematically characterize the proximal signaling network of this oncogenic kinase. The proximal BCR-ABL1 signaling network shows a modular and layered organization with an inner core of three leukemia transformation-relevant adaptor protein complexes (Grb2/Gab2/Shc1 complex, CrkI complex and Dok1/Dok2 complex).
View Article and Find Full Text PDFNucleic Acids Res
September 2010
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Institute for Molecular Medicine, Jonsson Comprehensive Cancer Center and California NanoSystems Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Comparing independent high-throughput gene-expression experiments can generate hypotheses about which gene-expression programs are shared between particular biological processes. Current techniques to compare expression profiles typically involve choosing a fixed differential expression threshold to summarize results, potentially reducing sensitivity to small but concordant changes. We present a threshold-free algorithm called Rank-rank Hypergeometric Overlap (RRHO).
View Article and Find Full Text PDFCancer Res
August 2010
Crump Institute for Molecular Imaging, University of California at Los Angeles, Los Angeles, California 90095, USA.
The clinical practice of oncology is being transformed by molecular diagnostics that will enable predictive and personalized medicine. Current technologies for quantitation of the cancer proteome are either qualitative (e.g.
View Article and Find Full Text PDFMol Imaging Biol
June 2011
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Box 951770, 570 Westwood Plaza, Los Angeles, CA, 90095-1770, USA.
Purpose: The objective of this article is to develop internalizing positron emission tomography (PET) reporter genes for tracking genetically modified T cells in vivo.
Procedures: The transmembrane and cytoplasmic domains of the human transferrin receptor (TfR) and CD5 were each fused to the carcinoembryonic (CEA) minigene N-A3 and expressed in Jurkat T cells. Internalization was evaluated by confocal microscopy or by intracellular uptake of ¹²⁵I-labeled anti-CEA scFv-Fc.
Mol Imaging Biol
February 2011
Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Introduction: Bioluminescence imaging, especially planar bioluminescence imaging, has been extensively applied in in vivo preclinical biological research. Bioluminescence tomography (BLT) has the potential to provide more accurate imaging information due to its 3D reconstruction compared with its planar counterpart.
Methods: In this work, we introduce a positron emission tomography (PET) radionuclide imaging-based strategy to validate the BLT results.
Angew Chem Int Ed Engl
May 2010
Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), Institute for Molecular Medicine (IMED), University of California, Los Angeles, 570 Westwood Plaza, Building 114, Los Angeles, CA 90095-1770, USA.
Eur J Nucl Med Mol Imaging
August 2010
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
Purpose: Prostate stem cell antigen (PSCA), a cell surface glycoprotein expressed in normal human prostate and bladder, is over-expressed in the majority of localized prostate cancer and most bone metastases. We have previously shown that the hu1G8 minibody, a humanized anti-PSCA antibody fragment (single-chain Fv-C(H)3 dimer, 80 kDa), can localize specifically and image PSCA-expressing xenografts at 21 h post-injection. However, the humanization and antibody fragment reformatting decreased its apparent affinity.
View Article and Find Full Text PDFSemin Nucl Med
May 2010
UCLA Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA.
Noninvasive molecular imaging approaches include nuclear, optical, magnetic resonance imaging, computed tomography, ultrasound, and photoacoustic imaging, which require accumulation of a signal delivered by a probe at the target site. Monoclonal antibodies are high affinity molecules that can be used for specific, high signal delivery to cell surface molecules. However, their long circulation time in blood makes them unsuitable as imaging probes.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
March 2010
Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, CA 90095, USA.
Point mutations in the phosphorylation domain of the Bcr-Abl fusion oncogene give rise to drug resistance in chronic myelogenous leukemia patients. These mutations alter kinase-mediated signaling function and phenotypic outcome. An information theoretic analysis of the correlation of phosphoproteomic profiling and transformation potency of the oncogene in different mutants is presented.
View Article and Find Full Text PDFNano Today
December 2009
Department of Molecular and Medical Pharmacology, Crump institute for Molecular Imaging (CIMI), Institute for Molecular Medicine (IMED), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, CA, USA.
Microfluidic reactors exhibit intrinsic advantages of reduced chemical consumption, safety, high surface-area-to-volume ratios, and improved control over mass and heat transfer superior to the macroscopic reaction setting. In contract to a continuous-flow microfluidic system composed of only a microchannel network, an integrated microfluidic system represents a scalable integration of a microchannel network with functional microfluidic modules, thus enabling the execution and automation of complicated chemical reactions in a single device. In this review, we summarize recent progresses on the development of integrated microfluidics-based chemical reactors for (i) parallel screening of in situ click chemistry libraries, (ii) multistep synthesis of radiolabeled imaging probes for positron emission tomography (PET), (iii) sequential preparation of individually addressable conducting polymer nanowire (CPNW), and (iv) solid-phase synthesis of DNA oligonucleotides.
View Article and Find Full Text PDFChem Commun (Camb)
March 2010
Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), University of California, Los Angeles, 570 Westwood Plazas, CNSI Building, Los Angeles, CA 90095-1770, USA.
We demonstrated a convenient, flexible and modular synthetic approach for preparation of a small library of DNA-encapsulated supramolecular nanoparticles SNPs superset DNA and RGD-SNPs superset DNA with different sizes and RGD target ligand coverage for targeted gene delivery.
View Article and Find Full Text PDFBioprocess Int
February 2010
Pete Gagnon is principal consultant at Validated Biosystems Inc., 240 Avenida Vista Montana, Suite 7F, San Clemente, CA USA 92672; 1-949-276-7477, fax 1-949-606-1904; www.validated.com . Chia-Wei Cheung, Mark A. Sherman, Andrew A. Raubitschek, and Paul J. Yazaki are with the department of cancer immunotherapeutics and tumor immunology at the City of Hope Medical Center's Beckman Research Institute in Duarte, CA; www.cityofhope.org/research/beckman-research-institute . Eric J. Lepin and Anna M. Wu are with the Crump Institute for Molecular Imaging's department of molecular and medical pharmacology at UCLA's David Geffen School of Medicine in Los Angeles, CA; www.crump.ucla.edu.
This case study describes early phase purification process development for a recombinant anticancer minibody produced in mammalian cell culture. The minibody did not bind to protein A. Cation-exchange, anion-exchange, hydrophobic-interaction, and hydroxyapatite (eluted by phosphate gradient) chromatographic methods were scouted, but the minibody coeluted with BSA to a substantial degree on each.
View Article and Find Full Text PDFPhys Med Biol
February 2010
Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Dual-energy x-ray computed tomography (DECT) has the capability to decompose attenuation coefficients using two basis functions and has proved its potential in reducing beam-hardening artifacts from reconstructed images. The method typically involves two successive scans with different x-ray tube voltage settings. This work proposes an approach to dual-energy imaging through x-ray beam filtration that requires only one scan and a single tube voltage setting.
View Article and Find Full Text PDFProtein Eng Des Sel
April 2010
Department of Molecular and Medical Pharmacology, UCLA Crump Institute for Molecular Imaging, Los Angeles, CA 90095, USA.
Rapid clearing engineered antibody fragments for immunoPET promise high sensitivity at early time points. Here, tumor targeting of anti-CD20 diabodies (scFv dimers) for detection of low-grade B-cell lymphomas were evaluated. In addition, the effect of linker length on oligomerization of the diabody was investigated.
View Article and Find Full Text PDFCommun Numer Methods Eng
January 2009
David Geffen School of Medicine at UCLA, Crump Institute for Molecular Imaging, University of California, 700 Westwood Plaza, Los Angeles, CA 90095, USA.
Whole-body optical molecular imaging of mouse models in preclinical research is rapidly developing in recent years. In this context, it is essential and necessary to develop novel simulation methods of light propagation for optical imaging, especially when a priori knowledge, large-volume domain and a wide-range of optical properties need to be considered in the reconstruction algorithm. In this paper, we propose a three dimensional parallel adaptive finite element method with simplified spherical harmonics (SP(N)) approximation to simulate optical photon propagation in large-volumes of heterogenous tissues.
View Article and Find Full Text PDFAngew Chem Int Ed Engl
January 2010
Crump Institute for Molecular Imaging (CIMI), Institute for Molecular Medicine (IMED), Department of Molecular and Medical Pharmacology, California NanoSystems Institute (CNSI), University of California, Los Angeles, 570 Westwood Plaza, Building 114, Los Angeles, CA 90095-1770, USA.
Phys Med Biol
November 2009
Crump Institute for Molecular Imaging, Department of Medical and Molecular Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
It has been observed that microfluidic chips used for synthesizing (18)F-labeled compounds demonstrate visible light emission without nearby scintillators or fluorescent materials. The origin of the light was investigated and found to be consistent with the emission characteristics from Cerenkov radiation. Since (18)F decays through the emission of high-energy positrons, the energy threshold for beta particles, i.
View Article and Find Full Text PDFPhys Med Biol
November 2009
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Bioluminescence imaging has been extensively applied to in vivo small animal imaging. Quantitative three-dimensional bioluminescent source information obtained by using bioluminescence tomography can directly and much more accurately reflect biological changes as opposed to planar bioluminescence imaging. Preliminary simulated and experimental reconstruction results demonstrate the feasibility and promise of bioluminescence tomography.
View Article and Find Full Text PDFOpt Express
September 2009
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Bioluminescence imaging is a very sensitive imaging modality, used in preclinical molecular imaging. However, in its planar projection form, it is non-quantitative and has poor spatial resolution. In contrast, bioluminescence tomography (BLT) promises to provide three dimensional quantitative source information.
View Article and Find Full Text PDFJ Nucl Med
September 2009
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
Unlabelled: The CD20 cell surface antigen is expressed at high levels by over 90% of B-cell non-Hodgkin lymphomas (NHL) and is the target of the anti-CD20 monoclonal antibody rituximab. To provide more sensitive, tumor-specific PET imaging of NHL, we sought to develop PET agents targeting CD20.
Methods: Two recombinant anti-CD20 rituximab fragments, a minibody (scFv-C(H)3 dimer; 80 kDa) and a modified scFv-Fc fragment (105 kDa), designed to clear rapidly, were generated.